Special Issue

Multiple Sclerosis: Research in Remyelination, the Next Step

Message from the Guest Editors

In the last 30 years, the therapeutic developments in multiple sclerosis (MS) have been incessant and we already have a large number of drugs that have changed the natural history of the disease. These drugs are intended to modify the inflammatory mechanisms that occur, but have not directly addressed the repair of the damage that occurs. Many researchers consider that the action on demyelination-remyelination is the next step in MS research. Many questions are still open regarding the mechanisms of remyelination, the experimental models for research directed to this mechanism, the diagnostic methods focused on being able to analyze the presence and degree of remyelination, the designs of clinical trials to be able to evaluate these drugs, and regarding the consequences they can have on patient quality of life. This Special Issue aims to review the state-of-the-art of research on remyelination in MS, including mechanisms, directed research models, diagnosis, and therapeutic research.

Guest Editors

Prof. Dr. Jorge Matias-Guiu

Dr. Ulises Gomez-Pinedo

Prof. Dr. Oscar Gonzalez-Perez

Deadline for manuscript submissions

closed (19 August 2022)



Life

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 6.0
Indexed in PubMed



mdpi.com/si/98680

Life
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
life@mdpi.com

mdpi.com/journal/ life





Life

an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Life (ISSN 2075-1729) is an international, peer-reviewed open access journal that publishes scientific studies related to fundamental themes in life sciences. Some papers are published individually, while others are submitted for inclusion in special issues with guest editors. You are invited to contribute a research article, essay, or a review to be considered for publication.

Editor-in-Chief

Prof. Dr. Lluís Ribas de Pouplana

Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biology) / CiteScore - Q1 (Paleontology)

